Lorenzo Sabatelli - Department of Physics, Trinity College

基本信息

浏览量：18

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 37 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

EE78 Economic and Comorbidity Burden of Prurigo Nodularis and Drivers of Higher Healthcare Costs in the US: A Retrospective Analysis of Claims Data of Patients Diagnosed Between 2017 and 2022

S Elmariah,N Princic, M Richards, A Qureshi,L Sabatelli, SG Kwatra

Value in Healthno. 6 (2024): S71-S72

引用0浏览0引用

Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study

David Michonneau,Raynier Devillier,Mikko Keranen,Marie Therese Rubio,Malin Nicklasson, Helene Labussiere-Wallet,Martin Carre,Anne Huynh, Elisabet Viayna,Montserrat Roset, Jonathan Finzi, Minja Pfeiffer, Daniel Thunstrom,Nuria Lara,Lorenzo Sabatelli,Patrice Chevallier,Maija Itala-Remes

HEMATOLOGY REPORTSno. 2 (2024): 283-294

引用0浏览0WOS引用

POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (soc) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R/R DLBCL): A Matching Adjusted Indirect Treatment Comparison (MAIC)

R. Cordoba,T. Prawitz,T. Westley, A. Sharma,V Kapetanakis,L. Sabatelli

VALUE IN HEALTH（2022）

引用0浏览0引用

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison

Cordoba Raul,Prawitz Thibaud,Westley Tracy, Sharma Anuj,Ambarkhane Sumeet,Kapetanakis Venediktos,Sabatelli Lorenzo

Advances in therapy（2022）

引用6浏览0WOS引用

Ponatinib Vs. Imatinib As Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

Josep-Maria Ribera,Thibaud Prawitz,Andreas Freitag, Anuj Sharma,Balázs Dobi, Federica Rizzo,Lorenzo Sabatelli, Petros Patos

Value in health（2022）

引用0浏览0WOS引用

CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches

R Córdoba,PL Zinzani,E Joffe,DH Yoon, A Peters,EE Waltl, C Alvero,L Sabatelli, G Salles,GS Nowakowski

Value in Health（2022）

引用0浏览0引用

Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study

Lorenzo Sabatelli,Mikko Keränen, Elisabet Viayna,Montserrat Roset,Nuria Lara, Daniel Thunström, Minja Pfeiffer,Malin Nicklasson,Maija Itälä-Remes

Support Care Cancer（2022）

引用0浏览0WOS引用

ABCL-088 Subgroup Analysis in RE-MIND2: an Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Grzegorz Nowakowski,Dok Hyun Yoon,Erel Joffe,Pier Luigi Zinzani,Lorenzo Sabatelli,Eva E. Waltl,Carmelita G. Alvero,Georg Hess,Peter Riedell,Kibum Kim,Diana Brixner,Gilles Salles

Clinical Lymphoma Myeloma & Leukemia（2022）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn